Could a hormone Flip-Flop tame tough prostate cancer?

NCT ID NCT05081193

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a two-step treatment in 15 men with metastatic castration-resistant prostate cancer. First, they took high-dose oral testosterone for three 28-day cycles. If the cancer grew, they switched to enzalutamide. The goal was to see if oral testosterone could control the cancer as well as injected testosterone, and whether the sequence might improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
testosterone undecanoate (Jatenzo) and enzalutamide (Xtandi)
What this could lead to
If it works, this could point toward a new treatment sequence that uses high-dose oral testosterone to control prostate cancer before switching to enzalutamide.
What could go wrong
This is a very small, early-phase study (15 men) with no control group. The approach is experimental and may not provide lasting benefit or work for most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15212, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.